• Henrik received his MSc degree in organic chemistry from Stockholm University in 2011. After the degree he started working with radiochemistry at Karolinska Institutet, in Christer Halldin research group, and in 2016 he joined the Radiopharmacy group at Karolinska University Hospital.

     

  • In 2023, he started as a PhD student with a focus on developing targeted alpha therapy for high-risk neuroblastoma.

  • Research

    Articles

    News from KI

    Events from KI